Summit Call Recap – January 22, 2015
- Registration for the National Adult and Influenza Immunization Summit Face-to-Face, Invitation Only Meeting Now Open!
- Nominations Now Open for 2015 NAIIS Immunization Excellence Awards (Deadline – February 13, 2015)
Information from CDC
- CDC/Influenza Division Weekly Influenza Surveillance Report and CDC Key Points
- CDC has New Widget for Antiviral Drugs
- CDC Health Advisory on Measles Outbreak Published on January 23, 2015
- Latest Social Media Messages
- Upcoming and Recent CDC COCA Calls
- CDC Releases New Measles Information to Assist Partners and Seeks Dissemination Support!
- Exemption Bills Introduced in West Virginia
- 2nd Asia-Pacific Influenza Summit June 11–12, 2015
- FDA Gives Green Light to Novartis Vaccine Bexsero
- Pfizer’s Prevenar 13 Gets CHMP Positive Opinion for Prevention of Vaccine-type Pneumococcal Pneumonia in Adults
- Many U.S. Girls Aren’t Getting HPV Vaccine, Study Finds
- Mandatory Flu Shots: Why One N.J. Hospital had 4,400 Employees Vaccinated
- Canada Reports H7N9 Avian Influenza Case in British Columbia
- Avian Flu Confirmed in Commercial Turkey Flock in California
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) holds 3rd Conference on Vaccines
- Public Health Foundation Offers Discount on Print Flu Materials for Summit Partners
- Every Child By Two (ECBT) Compiles Media Information on Its Website
- Summit Website Offers Wonderful Resources on Influenza Vaccination
SUMMIT CALL RECAP – JANUARY 22, 2015
Influenza Surveillance Update – Sophie Smith (CDC)
Sophie provided a summary of the published reports for week 1, ending January 10, 2015. A variety of measures indicate influenza activity is continuing to increase in the U.S.
The ILI-Net national data indicated 4.4% of total outpatient visits were for influenza-like illness (ILI), which is above the national baseline. Approximately 20.2% of specimens submitted for testing were positive, which is slightly lower than the level of the previous week. Of the deaths reported through the 122 Cities Mortality Reporting System during week 1, 8.5% were attributed to pneumonia and influenza (P&I), above the 7.0% epidemic threshold for the week. Reports indicated there were 29.9 laboratory-confirmed influenza-associated hospitalizations per 100,000 population.
Nineteen influenza-associated pediatric deaths were reported to CDC during the week 1, though some of these reports were for deaths which had occurred in earlier weeks. Eight deaths were associated with an influenza A (H3) virus, nine deaths were associated with an influenza A virus for which subtyping was not performed, one death was associated with an influenza virus for which the type was not determined, and one death was from an influenza B virus which occurred during week 1. A total of 45 pediatric deaths have been reported during the 2014–2015 season. Of the 37 for whom vaccination status was known, two were ineligible for vaccination, and only three were fully vaccinated.
As shown in CDC’s weekly influenza summary map, the geographic spread for influenza for week 1 is:
- Widespread – 46 states and Guam
- Regional – 3 states, Puerto Rico, Virgin Islands
- Local – 1 state and District of Columbia
- Sporadic – no states
- No activity – no states
- No report – no states
Since October 1, CDC has antigenically characterized 462 influenza viruses; 10 2009 H1N1 virus, 349 influenza A (H3N2) viruses, and 103 influenza B viruses. All 10 of the 2009 H1N1 viruses tested were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2014–2015 Northern Hemisphere influenza vaccine. Of the 349 influenza A (H3N2) viruses tested, 122 (35.0%) were characterized as A/Texas/50/2012-like, which also is included in this season’s Northern Hemisphere vaccine. Two hundred twenty-seven (65.0%) viruses tested showed either reduced titers with antiserum produced against A/Texas/50/2012 or belonged to a genetic group that typically shows reduced titers to A/Texas/50/2012. Among viruses that showed reduced titers with antiserum raised against A/Texas/50/2012, most were antigenically similar to A/Switzerland/9715293/2013, the H3N2 virus selected for the 2015 Southern Hemisphere influenza vaccine. Both B/Victoria and B/Yamagata-lineage viruses are circulating in the U.S. All 69 B/Yamagata-lineage viruses were characterized as B/Massachusetts/2/2012-like, a component of both the trivalent and quadrivalent vaccines for the Northern Hemisphere. Thirty (88.2%) of the 34 B/Victoria viruses were characterized as B/Brisbane/60/2008-like, a component of the 2014–2015 Northern Hemisphere quadrivalent influenza vaccine. Four (11.8%) of the B/Victoria lineage viruses tested showed reduced titers to B/Brisbane/60/2008.
None of 619 specimens tested this season have shown resistance to oseltamivir or zanamivir, and none of 517 specimens tested have shown resistance to peramivir.
One Summit member asked for more information related to an Epi-X report of parotitis associated with influenza in Tennessee. Sophie will check to find someone who can provide additional information during a future call. Carolyn also stated that she would be sure Summit members received additional information when anything was published on the website.
Announcements – Carolyn Bridges (CDC)
Carolyn announced that registration is now open for the 2015 NAIIS meeting to be held May 12–14 in Atlanta. A draft agenda and information on reserving a hotel room through the Summit block are also on the website. Participants needing a federal government rate should contact LaDora Woods. Carolyn reminded partners that earlier today LaDora sent an email to all Summit partners which included the case-sensitive password needed for registration.
Nominations are open now through February 13 for the 2015 NAIIS Immunization Excellence Awards. The nomination form and additional information are available online. The six categories for this year’s awards are shown on the website and include the NEW category of Adult Immunization Publication Award. This award was established to encourage publication of some of the great work being done by Summit members which may not have made it into the literature. The Summit wants to encourage publication of these types of activities so that persons who were unable to attend the meeting would still be able to learn about them.
Carolyn also reminded partners that CDC continues to look for descriptions of effective, evidence-based strategies for increasing adult vaccination rates that can be highlighted in a What Works factsheet. Persons needing additional information should contact Susan Farrall at CDC.
One partner asked for clarification on the publication dates for the updated adult immunization schedule. Carolyn reported that the schedule will be published on Tuesday, February 3, in print and electronic form in the Annals of Internal Medicine and on the CDC website. Finally, a Notice to Readers about the publication will be included in the MMWR on Thursday, February 5. The issue also will include an updated report on adult vaccination coverage for vaccines other than influenza.
Registration for the National Adult and Influenza Immunization Summit Face-to-Face, Invitation Only Meeting Now Open!
The 2015 National Adult and Influenza Immunization Summit (NAIIS) will take place on May 12–14, 2015 in Atlanta, Georgia. A basic agenda and registration information are available on the Summit website. (Note: The password needed for registration to this invitation-only meeting has been shared directly with Summit members or may be obtained by contacting LaDora Woods. After registering for the meeting, please be sure to follow the links to reserve a room using the hotel rooming block. This will allow Summit organizers to track registration with rooming, as well as helping us meet our rooming requirements with the hotel.
Nominations Now Open for 2015 NAIIS Immunization Excellence Awards (Deadline – February 13, 2015)
Give national recognition to those working to improve public health! The National Adult and Influenza Immunization Summit (NAIIS) is soliciting candidates for the 2015 NAIIS Immunization Excellence Awards. The 2015 awards recognize individuals and organizations that have made extraordinary contributions towards improving vaccination rates within their communities during 2014. The awards focus on individuals and organizations that exemplify the meaning of the “immunization neighborhood” (collaboration, coordination, and communication among immunization stakeholders dedicated to meeting the immunization needs of the patient and protecting the community from vaccine-preventable diseases). Unless an award criteria is specifically focused on influenza, it is the intent of the Summit to recognize broader adult immunization activities.
A National Winner will be selected for each award category, and where appropriate an Honorable Mention recipient. The winners will be presented with their awards at the NAIIS meeting which is being held on May 12–14, 2015 in Atlanta, GA. The national winner in each category will be invited to present their programs at the meeting.
The six categories of recognition are:
- Influenza Season Campaign
- Healthcare Personnel Campaign
- “Immunization Neighborhood” Champion
- Adult Immunization Champion
- Corporate Campaign
- NEW! Adult Immunization Publication Award
Additional information and the nomination submission form may be found online. (Note: The nomination deadline is February 13, 2015.)
INFORMATION FROM CDC
CDC/Influenza Division Weekly Influenza Surveillance Report and CDC Key Points
The CDC weekly influenza surveillance report for week 2, 2015 (ending January 17, 2015) and region specific data are now available. During week 2, 9.3% of all deaths reported through the 122 Cities Mortality Reporting System were due to pneumonia and influenza (P&I). This percentage was above the epidemic threshold of 7.1% for week 2.
For the 2014–2015 influenza season, CDC/Influenza Division and the National Center for Health Statistics (NCHS) are collaborating on a pilot project to use NCHS mortality surveillance data for the rapid assessment of P&I mortality. To view the data, please click here (http://www.cdc.gov/flu/weekly/nchs.htm).
About 141 (35.7%) of the 395 H3N2 viruses tested have been characterized as A/Texas/50/2012-like, the influenza A (H3N2) component of the 2014–2015 Northern Hemisphere influenza vaccine. 254 (64.3%) of the 395 viruses tested showed either reduced titers with antiserum produced against A/Texas/50/2012 or belonged to a genetic group that typically shows reduced titers to A/Texas/50/2012. Among viruses that showed reduced titers with antiserum raised against A/Texas/50/2012, most were antigenically similar to A/Switzerland/9715293/2013, the H3N2 virus selected for the 2015 Southern Hemisphere influenza vaccine. A/Switzerland/9715293/2013 is related to, but antigenically and genetically distinguishable, from the A/Texas/50/2012 vaccine virus. A/Switzerland-like H3N2 viruses were first detected in the United States in small numbers in March of 2014 and began to increase through the spring and summer.
Sixty-nine (67.0%) of the influenza B viruses tested belong to B/Yamagata/16/88 lineage, and the remaining 34 (33.0%) influenza B viruses tested belong to B/Victoria/02/87 lineage.
Eleven influenza-associated pediatric deaths were reported to CDC during week 2. Three deaths were associated with an influenza A (H3) virus and occurred during weeks 51, 53, and 1 (weeks ending December 20, 2014, January 3, and January 10, 2015, respectively). Eight deaths were associated with an influenza A virus for which no subtyping was performed and occurred during weeks 51, 52, 53, 1, and 2 (weeks ending December 20, December 27, 2014, and January 3, January 10, and January 17, 2015, respectively).
A total of 56 influenza-associated deaths have been reported during the 2014-2015 season from New York City  and 23 states (Arizona , Colorado , Florida , Georgia , Indiana , Iowa , Kansas , Kentucky , Louisiana , Michigan , Minnesota , Missouri , North Carolina , Nevada , Ohio , Oklahoma , Pennsylvania , South Carolina , South Dakota , Tennessee , Texas , Virginia , and Wisconsin ). More detail is available on the FluView website.
Between October 1, 2014 and January 17, 2015, 9,926 laboratory-confirmed influenza-associated hospitalizations were reported. The overall hospitalization rate was 36.3 per 100,000 population. The highest rate of hospitalization was among adults aged ≥65 years (176.1 per 100,000 population), followed by children aged 0–4 years (34.5 per 100,000 population). Among all hospitalizations, 9,597 (96.8%) were associated with influenza A, 244 (2.5%) with influenza B, 25 (0.2%) with influenza A and B co-infection, and 52 (0.5%) had no virus type information. Among those with influenza A subtype information, 2,623 (99.7%) were A(H3N2) virus and seven (0.3%) were A(H1N1)pdm09. Additional virus characterization is available on FluView.
Nationwide during week 2, 4.5% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is above the national baseline of 2.0%. ILI is defined as fever (temperature of 100°F [37.8°C] or greater), and cough and/or sore throat. An Influenza Summary Update of the influenza activity reported by state and territorial epidemiologists, which indicates geographic spread of influenza viruses but does not measure the intensity of influenza activity, is available. This currently reflects data from January 17, 2015. At this time, most states are reporting widespread influenza activity.
The FluView report for week 2 (ending January 17, 2015) and archives of previous FluViews are available from CDC. CDC also has released seasonal influenza key points for January 23, 2015.
CDC has New Widget for Antiviral Drugs
Clinicians – CDC has a new widget, the Influenza Antiviral Widget for Clinicians, to help test your knowledge about influenza antiviral drugs.
CDC Health Advisory on Measles Outbreak Published on January 23, 2015
U.S. Multi-state Measles Outbreak, December 2014–January 2015
The Centers for Disease Control and Prevention (CDC) and State Health Departments are investigating a multi-state outbreak of measles associated with travel to Disneyland Resort Theme Parks (which includes Disneyland and Disney California Adventure). The purpose of this HAN Advisory is to notify public health departments and healthcare facilities about this measles outbreak and to provide guidance to healthcare providers. Healthcare providers should ensure that all of their patients are current on MMR (measles, mumps, and rubella) vaccine. They should consider measles in the differential diagnosis of patients with fever and rash and ask patients about recent international travel or travel to domestic venues frequented by international travelers. They should also ask patients about their history of measles exposures in their community. Please disseminate this information to healthcare providers in hospitals and emergency rooms, to primary care providers, and to microbiology laboratories.
Measles is a highly contagious, acute viral illness. It begins with a prodrome of fever, cough, coryza (runny nose), conjunctivitis (pink eye), lasting 2-4 days prior to rash onset. Measles can cause severe health complications, including pneumonia, encephalitis, and death. Measles is transmitted by contact with an infected person through coughing and sneezing; infected people are contagious from 4 days before their rash starts through 4 days afterwards. After an infected person leaves a location, the virus remains viable for up to 2 hours on surfaces and in the air.
The United States is experiencing a large multi-state measles outbreak that started in California in December 2014 and has spread to six additional states and Mexico. The initial confirmed case-patients reported visiting Disneyland Resort Theme Parks in Orange County, CA, from December 17 through December 20, 2014. From December 28, 2014, through January 21, 2015, 51 confirmed cases of measles linked to this outbreak have been reported to CDC, 42 from California and 9 from six other states (3 in UT, 2 in WA, 1 in OR, 1 in CO, 1 in NE, and 1 in AZ). In addition to the U.S. cases, one case was reported from Mexico in an unvaccinated child who visited Disneyland Resort Theme Parks on December 17 and December 20, 2014. At this time, no source case for the outbreak has been identified, but it is likely that a traveler (or more than one traveler) who was infected with measles overseas visited one or both of the Disney parks in December during their infectious period.
For cases with age reported, the age of case-patients range from 10 months to 57 years (median = 16.5 years). To date, 8 (15%) case-patients were hospitalized. Of the 52 outbreak-associated cases, 28 (55%) were unvaccinated, 17 (31%) had unknown vaccination status, and 6 (12%) were vaccinated. Of the 6 cases vaccinated, 2 had received 1 dose and 4 had received 2 or more doses. Among the 28 unvaccinated cases, 5 were under age for vaccination. Measles genotype information was available from 9 measles cases; all were genotype B3 and all sequences linked to this outbreak are identical. The sequences are also identical to the genotype B3 virus that caused a large outbreak in the Philippines in 2014. During the last 6 months, identical genotype B3 viruses were also detected in at least 14 countries and at least 6 U.S. states, not including those linked to the current outbreak.
Measles was declared eliminated (i.e., interruption of year-round endemic transmission) in the United States in 2000, because of high population immunity achieved by high 2-dose measles vaccine coverage and a highly effective measles vaccine. However, measles is still endemic in many parts of the world, and outbreaks can occur in the U.S. when unvaccinated groups are exposed to imported measles virus. In 2014, nearly half of importations in the U.S. were linked to travel to the Philippines during the large measles outbreak in that country. Disney and other theme parks are international attractions, and visitors come from many parts of the world, including locations where measles is endemic. The current multi-state outbreak underscores the ongoing risk of importation of measles, the need for high measles vaccine coverage, and the importance of a prompt and appropriate public health response to measles cases and outbreaks.
Because of the success of the measles vaccine program, most young physicians have never seen a case of measles and may not take a detailed history of travel or potential exposure and initially may not consider the diagnosis in a clinically compatible case.
Recommendations for Health Care Providers
- Ensure all patients are up to date on MMR vaccine* and other vaccines.
- For those who travel abroad, CDC recommends that all U.S. residents older than 6 months be protected from measles and receive MMR vaccine, if needed, prior to departure.
- Infants 6 through 11 months old should receive 1 dose of MMR vaccine before departure†
- Children 12 months of age or older should have documentation of 2 doses of MMR vaccine (separated by at least 28 days).
- Teenagers and adults without evidence of measles immunity** should have documentation of 2 appropriately spaced doses of MMR vaccine.
- Consider measles as a diagnosis in anyone with a febrile rash illness and clinically compatible symptoms (cough, coryza, and/or conjunctivitis) who has recently traveled abroad or who has had contact with someone with a febrile rash illness. Immunocompromised patients may not exhibit rash or may exhibit an atypical rash. The incubation period for measles from exposure to fever is usually about 10 days (range, 7 to 12 days) and from exposure to rash onset is usually 14 days (range, 7 to 21 days).
- Isolate suspect measles case-patients and immediately report cases to local health departments to ensure a prompt public health response.
- Obtain specimens for testing, including viral specimens for confirmation and genotyping. Contact the local health department for assistance with submitting specimens for testing.
* Children 1 through 12 years of age may receive MMRV vaccine for protection against measles, mumps, rubella, and varicella.
† Infants who receive a dose of MMR vaccine before their first birthday should receive 2 more doses of MMR vaccine, the first of which should be administered when the child is 12 through 15 months of age and the second at least 28 days later.
** One of the following is considered evidence of measles immunity for international travelers: 1) birth before 1957, 2) documented administration of 2 doses of live measles virus vaccine (MMR, MMRV, or measles vaccines), 3) laboratory (serologic) proof of immunity or laboratory confirmation of disease.
For more information:
- CDC: Measles–United States, January 1–May 23, 2014. MMWR. 2014;63:496–499.
- CDC website: Measles (Rubeola)
- CDC’s website: Measles Vaccination
- Notes from the Field: Measles Transmission at a Domestic Terminal Gate in an International Airport — United States, January 2014. MMWR. 2014; 63):1211-1211.
- Medscape Today: CDC Expert Commentary: Measles: What You Might Not Know (recognizing, diagnosing, and preventing measles) (running time: 5:20 minutes)
- CDC: Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 2013;62(RR04);1–34.
CDC: Manual for the Surveillance of Vaccine-Preventable Diseases; Chapter 7: Measles.
Latest Social Media Messages
CDC’s Influenza Division has developed the following social media messages that your organization may use to help communicate about influenza and flu activity. These can be tweeted using your organization’s Twitter handle or adapted for use on other social media platforms.
- #Flu activity in the U.S. is widespread and likely to continue for weeks. http://1.usa.gov/1dgiUJY
- Aches? Fever? Fatigue? You may have the #flu. Know what to do if you get sick: http://1.usa.gov/1b4LGNv #fightflu
- #FluTip: While sick, limit contact with others as much as possible to keep from infecting them. http://1.usa.gov/IKbYts
- Who should get treated with antivirals? Get answers here: http://1.usa.gov/1dXjzOM
- Prompt use of antivirals is key this #flu season. Learn more about this impt step: http://1.usa.gov/1dXjzOM
- Children and older adults are being harder hit this #flu season. Protect your loved ones: http://1.usa.gov/1cGv6jr
#Clinicians: What’s your #flu antivirals I.Q.? Find out with this new quiz: http://1.usa.gov/1EaNBPs
Upcoming and Recent CDC COCA Calls
2014–2015 Influenza Activity and Antiviral Recommendations
The latest FluView report indicates that flu activity remains high in the United States and is now widespread in 46 states and Guam. It has been recognized for many years that people 65 years and older are at higher risk of serious complications from the flu, and this flu season the hospitalization rates in this age group are climbing steeply. CDC recommends that all hospitalized and high risk patients (either hospitalized or outpatient) with suspected influenza should be treated as soon as possible with one of three available influenza antiviral medications, without waiting for confirmatory influenza testing. During this COCA Webinar, 2014–2015 Influenza Activity and Antiviral Recommendations, clinicians learned about 2014-2015 influenza activity, heard a summary of CDC’s current antiviral recommendations, and discussed data that inform the antiviral recommendations.
CDC Releases New Measles Information to Assist Partners and Seeks Dissemination Support!
The United States is experiencing a large multi-state measles outbreak that started in California in December 2014 and has spread to six additional states and Mexico. From December 28, 2014, through January 21, 2015, 51 confirmed cases of measles linked to this outbreak have been reported to CDC. Because many doctors currently in practice may not be familiar with measles signs and symptoms, CDC is asking for your help to raise awareness about measles among your members.
Here’s what you can do:
Send an e-mail blast to your members.
CDC drafted the following message that you can share with healthcare professionals in your network:
From December 28, 2014 through January 21, 2015, more than 50 people from six states were reported to have measles. Most of these cases are part of a large, ongoing outbreak linked to an amusement park in California. CDC urges healthcare professionals to consider measles when evaluating patients with febrile rash and ask about a patient’s recent international travel history and travel to domestic venues frequented by international travelers.
What Should Clinicians Do?
- Ensure all patients are up to date on measles, mumps, rubella (MMR) vaccine.
- Consider measles in patients presenting with febrile rash illness and clinically compatible measles symptoms (cough, coryza, and conjunctivitis), and ask patients about recent travel internationally or to domestic venues frequented by international travelers, as well as a history of measles exposures in their communities.
- Promptly isolate patients with suspected measles to avoid disease transmission and immediately report the suspect measles case to the health department.
- Obtain specimens for testing from patients with suspected measles, including viral specimens for genotyping, which can help determine the source of the virus. Contact the local health department with questions about submitting specimens for testing.
For more information, including guidelines for patient evaluation, diagnosis and management, visit CDC’s Measles (Rubeola) website for Healthcare Professionals.
Post a “Think Measles” button and banner on your websites and blogs targeting healthcare professionals.
CDC’s measles web button and banner will remind clinicians to consider measles diagnoses. They link to CDC’s measles webpage for healthcare professionals.
Share information about measles with parents and the public.
CDC has a recent article for parents about measles that you can link to from your consumer-friendly websites.
Learn more about measles and encourage your members to do the same.
Below is information about measles that you can promote to other healthcare professionals:
- View an archived Immunization NetConference (CIINC) from 2014
- View a CDC Expert Commentary about measles video on Medscape about measles
CDC thanks you for your assistance!
Exemption Bills Introduced in West Virginia
Senate Bill 286 was introduced in West Virginia last Friday, January 23. If passed, this bill will 1) allow religious exemptions to the school immunization requirements; 2) remove the medical exemption review process; and 3) remove the 7th and 12th grade requirements for Tdap and meningococcal vaccination.
House Bill 2258, which is called the Parents’ Bill of Rights, was also introduced. While this one looks nice on the surface, its purpose is to allow religious exemptions.
West Virginia is one of two states that do not allow religious exemptions.
2nd Asia-Pacific Influenza Summit June 11–12, 2015
The Asia-Pacific Alliance for the Control of Influenza (APACI) is pleased to announce the 2nd Asia-Pacific Influenza Summit, to take place June 11 & 12, in Hanoi, Vietnam. Please mark the dates on your calendar.
APACI continues to develop new initiatives to promote influenza awareness in the region, and will again be presenting a unique opportunity to meet with key influenza experts and stakeholders from within the region, and from around the world. The summit follows the success of the inaugural Asia-Pacific Influenza summit held in Bangkok in 2012.
The summit will take place immediately prior to the 2015 Asian Vaccine Conference.
FDA Gives Green Light to Novartis Vaccine Bexsero
The US Food and Drug Administration has approved the second vaccine in three months for the prevention of serogroup B meningococcal disease – Novartis’ Bexsero. Additional information may be found in articles from the PharmaTimes and thepharmaletter.
Pfizer’s Prevenar 13 Gets CHMP Positive Opinion for Prevention of Vaccine-type Pneumococcal Pneumonia in Adults
Pfizer announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the indication for Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older.
Many U.S. Girls Aren’t Getting HPV Vaccine, Study Finds
Only about half of American girls begin receiving the human papillomavirus (HPV) vaccine at the recommended age, a new study finds. The study found that the number of girls in the United States who started the vaccine series at the recommended age was 14 percent in 2008. By 2012, that number was 56 percent. The trends did not differ by race or ethnicity, according to the study published in the journal Vaccine.
Mandatory Flu Shots: Why One N.J. Hospital had 4,400 Employees Vaccinated
Education was key to putting a mandatory flu vaccine policy in place at Kennedy Health’s three hospitals. Looking at different flu shot policies across the state, the team at Kennedy knew it was time to establish a mandatory policy there.
Canada Reports H7N9 Avian Influenza Case in British Columbia
Canadian health officials today confirmed that an individual in B.C. has tested positive for the H7N9 avian influenza strain. The individual recently returned to Canada from China. This is the first documented case of H7N9 infection in a human in North America.
Avian Flu Confirmed in Commercial Turkey Flock in California
Federal agriculture officials say they have found avian influenza in a commercial turkey flock in central California. The U.S. Department of Agriculture said Saturday that the facility in Stanislaus County has been quarantined and birds from the affected flock will not enter the food system.
Testing occurred after the flock experienced a spike in deaths. Officials say there is no immediate public health concern and the detected strain — H5N8 — is not known to harm humans.
Stories about this confirmation have been carried by ABC News and The Modesto Bee.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) holds 3rd Conference on Vaccines
The ESCMID 3rd Conference on Vaccines – Vaccines for Mutual Protection will be held from 6 – 8 March 2015 in Lisbon, Portugal.
The abstract submission for young fellows is still open until 25 January 2015, and the current program and registration page are available online.
The conference is accredited with 15 CME points by the European Accreditation Council for Continuing Medical Education (EACCME), and provides an opportunity to meet with top-experts and participants to discuss the multiple aspects of direct and indirect protective effects of vaccination as well as novel approaches for vaccination in all ages.
Public Health Foundation Offers Discount on Print Flu Materials for Summit Partners
The CDC offers select flu print materials free for order. To filter the search for flu materials, in the Program drop-down box select “Immunizations and Vaccines (Influenza/Flu)”, then press Go. Order limits apply and usually require 2-4 weeks for delivery.
In an effort to broaden the availability of print materials, the Public Health Foundation (PHF) is partnering with CDC to provide health care professionals with resources to encourage patients to get their annual flu vaccination. Through its Learning Resource Center online store, the PHF is offering bulk copies of select flu materials for purchase. The PHF is offering a 25% discount on all flu materials to Summit Buzz readers through January 31, 2015 using code FLU015. Orders usually require 7 days for delivery.
A complete list of available materials, along with a description of the item, is shown below.
- Are You at Risk? Poster (pkg of 5) – This full-color poster informs patients and providers about the risks and complications of the flu, and the importance of getting a flu vaccine.
- Flu Complications Pad (Flu Shot Reminders Pad) (pkg of 10 pads) – This 4” x 6” pad includes 25 sheets and is customizable by physicians, public health personnel, healthcare professionals, pharmacists, and others to recommend the flu vaccine for patients at high risk for flu complications. This piece helps a provider identify patients with high risk conditions and gives examples of flu-related complications.
- I Won’t Spread Flu Poster (pkg of 5) – This full-color poster communicates the importance of flu prevention for providers in health care settings.
- Take 3 Actions to Fight Flu Brochure (pkg of 25) – This full-color, trifold brochure outlines three actions that everyone should take to prevent the flu.
- The Flu: A Guide for Parents Brochure – English (pkg of 25) – This full-color, trifold brochure provides parents and caregivers with useful information regarding the impact of flu on children, the importance of flu vaccination, and how to care for children with flu illness.
The Flu: A Guide for Parents Brochure – Spanish (pkg of 25) – This Spanish-language, full-color trifold brochure provides parents and caregivers with useful information regarding the impact of flu on children, the importance of flu vaccination, and how to care for children with flu illness.
Every Child By Two (ECBT) Compiles Media Information on Its Website
On a daily basis, ECBT assembles significant news media coverage on immunizations in their “Daily Clips.” Summit partners may find this effort useful.
Summit Website Offers Wonderful Resources on Influenza Vaccination
Remember to visit the Summit website for the latest on influenza immunization resources. You also can find archived copies of the Summit Buzz there.
Summit calls are scheduled every Thursday at 3 pm ET, unless cancelled. Please email L.J Tan or LaDora Woods if you have any updates on activities to provide to the Summit.